FOLD News and Press, Amicus Therapeutics Inc. From 04/27/22

Despite the bear market, Amicus Therapeutics is enjoying aggressive sales growth for its lead medicine, Galafold, for Fabry. By mid-year, you are most likely to see another approval, that is, AT-GAA for Pompe disease. As it's operating at a growth inflection point, you should pick...

PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2022. Inter...

Amicus Therapeutics (NASDAQ:FOLD) said the U.S. Patent and Trademark Office (USPTO) issued a patent which is directed to a composition of matter covering migalastat, sold as Galafold to treat Fabry disease. The company said the U.S. patent No. 11,304,940, titled 'Methods o...

PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the United States Patent and Trademark Office (USPT...

Although AT-GAA failed a phase 3 trial, there are reasons it could be approved. Galafold continues to do very well. I will hold until the July 29 PDUFA. For further details see: Amicus: July 29 PDUFA Makes It A Hold

Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) traded today at $25.34, eclipsing its 52-week high. Approximately 247.8 million shares have changed hands today, as compared to an average 30-day volume of 3.6 million shares. Amicus Therapeutics Inc is a biotechnology company focused on d...

Amicus Therapeutics (NASDAQ:FOLD) reported additional results from a global phase 1/2 study (ATB200-02) of AT-GAA in adult patients with Pompe disease. Pompe disease is an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease ...

Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk and Forced Vital Capacity for ERT-Naïve and ERT-Experienced Patients Out to 3 Years Consistent Reduction in Biomarkers Continue to Suggest a Positive Effect on Muscle Tissue S...

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2022 MDA Clinical & Scientific Conference , being held March ...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...